### FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

W	as	hi	nq	ton	, D	c.C	. 20	054	19

# ANNUAL STATEMENT OF CHANGES IN BENEFICIAL

	OMB APPROVAL								
	OMB Number:	3235-0362							
	Estimated average b	ourden							
- 1	l	1.0							

_	tion 1(b). Holdings Rep	OWNERSHIP								l II	Estimated average burden hours per response: 1.0						
Form 4	Transactions I	Reported.	Fi	led pursuant t or Section					rities Excha Company Ac								
1. Name and Address of Reporting Person*  Polymeropoulos Mihael Hristos					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Vanda Pharmaceuticals Inc. [ VNDA ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Midd 9605 MEDICAL CENTER DRIVE SUITE 300			Middle)	12/31/20	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2011							X Officer (give title Other (specify below)  President and CEO					
(Street) ROCKV			20850 (Zip)	- 4. If Amei	ndme	nt, Date	of Origi	inal File	ed (Month/E	Day/Year			n filed by n filed by	One Rep	g (Check / orting Per n One Re	son	
		Tab	le I - Non-Deri	vative Sed	curit	ies Ac	quire	ed, Di	sposed	of, or	Benefici	ally Own	ed				
Da			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) or Dispos Of (D) (Instr. 3, 4 and 5)			or Disposed	Securit Benefic	ies ially		rship II Direct E	. Nature of ndirect Beneficial Ownership	
						8)		Amount		(A) or (D)	Price	Issuer's	Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)			(Instr. 4)	
Common Stock			02/18/2011		M		Л	18,750		A	(1)	40	408,750		D		
		T	able II - Deriva (e.g., ¡	ative Secu puts, calls									t				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	of Deri Sec Acq (A) ( Disp of (E	wative urities uired or oosed O) (Instr. and 5)	Expira	Expiration Date (Month/Day/Year) Ar Se Ur		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		urity Derivative Security (Instr. 5)		mber of ative rities ficially ed wing rted saction(s)	10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership (Instr. 4)	
					(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amou or Numb of Share	er					
Restricted	(1)	02/18/2011		М		18 750	(2	2)	(3)	(3) Common 18		0 (1)	5	56.250			

#### **Explanation of Responses:**

- 1. Each Restricted Stock Unit represents a contigent right to receive a share of the Issuer's common stock.
- 2. The Restricted Stock Units vest in four equal annual installments beginning January 1, 2011. Vested shares will be delivered on the First Permissable Trading Day (as defined in the Restricted Stock Unit Agreement) that occurs on or after the day when the Restricted Stock Units vest.

3. N/A

## Remarks:

/s/ Mihael H. Polymeropoulos 02/13/2012

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.